Table 1

 Characteristics of 234 participants with asthma according to treatment with inhaled corticosteroids (ICS) during the follow up period

VariableWomenMen
No ICS(n = 114)On ICS(n = 33)p valueNo ICS(n = 76)On ICS(n = 11)p value
ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BMI, body mass index; ΔFEV1, decline in FEV1.
Data presented as mean (SD) values. Unless specified, all values are given at the beginning of the follow up period.
The information on asthma duration was only available in 125 of the participants.
Smokers are defined as participants who smoked tobacco at both the beginning and the end of the observation period.
Age (years)57.2 (11.3)57.9 (9.8)NS51.7 (12.7)58.4 (8.7)NS
FEV1(l)2.23 (0.65)1.74 (0.64)<0.0013.22 (0.99)2.07 (0.78)<0.001
FEV1 % predicted in 1991–488.3 (19.6)67.8 (20.5)0.00185.7 (20.6)60.2 (17.9)0.004
FEV1/FVC % in 1991–477.8 (8.6)66.4 (10.3)<0.00172.8 (10.7)61.1 (12.7)<0.001
Height (cm)163 (6.2)163 (6.8)NS176 (6.0)174 (7.2)NS
BMI (kg/m2)26.3 (5.4)26.0 (5.3)NS25.6 (4.9)25.6 (2.9)NS
Smoking 1991–2003 (%)32.524.2NS37.318.2NS
Asthma duration (years)*17.8 (18.4)14.6 (16.6)NS25.1 (20.1)12.7 (15.9)0.07
Chronic mucus hypersecretion (%)19.339.40.0220.036.4NS
Wheezing (%)64.093.9<0.00164.090.90.09
Hay fever (%)32.512.50.0332.027.3NS
ΔFEV1 (ml/year) 1991–200346.5 (31.5)25.8 (33.8)<0.00156.6 (54.5)21.1 (44.9)0.04
FEV1 % predicted in 2001–380.1 (21.7)66.2 (21.0)<0.00178.7 (22.7)61.3 (18.5)0.02
FEV1/FVC in 2001–373.6 (10.7)64.6 (10.4)<0.00169.8 (10.5)60.7 (13.1)<0.001